Who Owns Zyrtec?

• Parent Company: Kenvue
• Ownership Type: Wholly owned
• Company Type: Publicly Traded
• Stock Ticker: NYSE: KVUE

• Founded: 1987
• Founders: UCB Pharma (original developer)

• Founded: 2023
• Headquarters: Jersey City, New Jersey, USA
• Company Type: Publicly Traded
• Stock: NYSE: KVUE
• Revenue: approximately $14.9 billion (FY2024)
• Employees: Approximately 22,000

Visit Kenvue website

• Headquarters: New Brunswick, New Jersey, USA
• Manufacturing / Operations: United States, Europe, Asia

Zyrtec operates under Kenvue's comprehensive sustainability framework, which includes ambitious environmental initiatives and ethical business practices. As part of Kenvue's Healthy Lives Mission, Zyrtec benefits from the company's commitment to enriching healthy people, enriching a healthy planet, and maintaining healthy practices.

Kenvue has set significant sustainability targets that directly impact Zyrtec's operations and packaging. The company aims for 100% recyclable or refillable packaging by 2025, with a 25% reduction in virgin plastic use by 2025 and 50% reduction by 2030, using 2020 as the baseline year. These goals align with broader environmental commitments including a 42% reduction in Scope 1 and 2 greenhouse gas emissions by 2030.

Zyrtec has demonstrated leadership in sustainable packaging innovation. In 2024, the brand transitioned from clamshell packaging to paper-based designs, eliminating approximately 152,000 pounds of plastic annually. This change represents a significant reduction in the brand's environmental footprint while maintaining product quality and consumer accessibility.

The company follows circular economy principles through its "Four Rs" approach: Reduce (optimizing packaging through material efficiency), Replace (selecting recycled and renewable materials), Reuse (innovating refill-ready packaging), and Recover (designing packaging to be "recycle-ready"). Zyrtec's packaging redesign exemplifies these principles by replacing non-recyclable materials with recyclable alternatives.

Kenvue supports both mechanical and advanced recycling approaches, including chemical recycling that breaks plastics into basic monomer building blocks. This comprehensive recycling strategy helps ensure that Zyrtec packaging can be effectively processed through various recycling systems, supporting circular economy goals.

Zyrtec has received recognition for its marketing innovation and consumer health leadership, particularly in the allergy medication category. While specific industry awards for pharmaceutical products are less common than in consumer goods categories, Zyrtec has been acknowledged for effective consumer education and allergy awareness campaigns.

The brand has been recognized for its creative marketing approaches, including campaigns that combine fashion and seasonal allergy awareness. These initiatives have been acknowledged by marketing industry publications for their effectiveness in reaching consumers during peak allergy seasons while providing valuable health information.

Zyrtec's position as one of the leading non-drowsy antihistamine brands globally has been acknowledged by healthcare professionals and consumer health organizations. The brand's consistent performance in treating allergies without causing drowsiness has made it a trusted choice among consumers and healthcare providers.

Under Kenvue ownership, Zyrtec benefits from the parent company's broader recognition in consumer health. Kenvue's portfolio of iconic brands, including Neutrogena, Listerine, Aveeno, and Tylenol, has received industry acknowledgment for innovation and consumer trust, which reflects positively on all Kenvue brands including Zyrtec.

The brand's commitment to consumer education and allergy awareness has been recognized by patient advocacy groups and healthcare organizations. Zyrtec's efforts to help consumers understand allergy triggers and treatment options have contributed to improved public health outcomes and increased awareness of seasonal allergies.

Zyrtec has faced regulatory attention and safety concerns, particularly related to long-term usage effects and manufacturing standards. In May 2025, the FDA issued a warning about Zyrtec and its sister product Xyzal after 197 U.S. users reported "rare but severe itching" after discontinuing long-term use of these medications.

The FDA's May 16, 2025 announcement highlighted that customers who had taken these allergy medications routinely for months or years and then stopped using them reported experiencing pruritus (severe itching). Many affected users required medical attention due to the severity of their symptoms. As a result, the FDA requires updated packaging warnings about the risks of taking daily doses of these allergy medicines for extended periods.

In addition to the FDA warning, Zyrtec has been affected by broader drug safety recalls that impacted multiple over-the-counter medications. A massive drug safety recall included generic versions of popular medicines sold under brand names including Zyrtec, initiated over concerns that the products failed to meet current good manufacturing standards.

The recall, which affected both prescription and over-the-counter drugs, was initiated by manufacturers to remove potentially defective medications from the market. While these recalls primarily affected generic versions rather than the brand-name Zyrtec product, they highlighted ongoing quality control challenges in the pharmaceutical manufacturing industry.

Zyrtec has not faced major product-specific recalls related to formulation or safety issues. The brand's pharmaceutical heritage and rigorous testing processes have helped maintain product safety standards, though the FDA warnings about long-term usage effects have required additional consumer education and labeling updates.

The brand has navigated these challenges by maintaining transparency with consumers and healthcare providers, updating packaging information as required by regulatory agencies, and continuing to invest in product safety research and consumer education initiatives.